Breakthrough Trial Reveals Eli Lilly’s Obesity Pill Promises 12% Weight Loss
Pharmaceutical titan, Eli Lilly, has unveiled encouraging results from its Phase 3 trial of orforglipron. This innovative, once-daily oral obesity pill has demonstrated its potential by aiding patients in shedding an average of 12% of their body weight. This equates to a significant loss of approximately 27 pounds over a 72-week period.
The groundbreaking ATTAIN-1 trial involved 3,127 adults grappling with obesity. This trial marks a significant milestone in weight management. Orforglipron is poised to become the first non-injectable alternative to current GLP-1 injections such as Wegovy and Zepbound. Unlike existing oral options, this pill imposes no dietary restrictions and offers the convenience of being taken at any time of day.
“With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end,” the company announced. The medication exhibited impressive results with 59.6% of participants taking the highest dose losing at least 10% of their body weight. Furthermore, 39.6% achieved a weight loss of 15% or more. Lilly is planning a global launch pending FDA approval, with the pill potentially being available to patients as early as 2026.
For more information, visit the original article here.